Belite Bio to Participate in the BTIG Virtual Biotechnology Conference
Belite Bio (NASDAQ: BLTE), a clinical-stage biopharmaceutical company developing treatments for degenerative retinal diseases, announced its participation in the upcoming BTIG Virtual Biotechnology Conference scheduled for July 29-30, 2025.
The company's executive management team will be available for one-on-one meetings with investors during the conference, which can be arranged through BTIG representatives.
Belite Bio (NASDAQ: BLTE), un'azienda biofarmaceutica in fase clinica che sviluppa trattamenti per le malattie degenerative della retina, ha annunciato la sua partecipazione al prossimo BTIG Virtual Biotechnology Conference previsto per il 29-30 luglio 2025.
Il team di gestione esecutiva dell'azienda sarà disponibile per incontri individuali con gli investitori durante la conferenza, che possono essere organizzati tramite i rappresentanti di BTIG.
Belite Bio (NASDAQ: BLTE), una empresa biofarmacéutica en etapa clínica que desarrolla tratamientos para enfermedades degenerativas de la retina, anunció su participación en la próxima Conferencia Virtual de Biotecnología BTIG programada para el 29-30 de julio de 2025.
El equipo ejecutivo de la compañía estará disponible para reuniones individuales con inversores durante la conferencia, las cuales se pueden coordinar a través de los representantes de BTIG.
Belite Bio (NASDAQ: BLTE)는 퇴행성 망막 질환 치료제를 개발하는 임상 단계의 생명공학 기업으로, 2025년 7월 29-30일에 예정된 BTIG 가상 생명공학 컨퍼런스에 참여한다고 발표했습니다.
회사의 경영진 팀은 컨퍼런스 기간 동안 투자자들과의 1:1 미팅을 진행할 예정이며, 이는 BTIG 담당자를 통해 예약할 수 있습니다.
Belite Bio (NASDAQ : BLTE), une société biopharmaceutique en phase clinique développant des traitements pour les maladies dégénératives de la rétine, a annoncé sa participation à la prochaine Conférence Virtuelle de Biotechnologie BTIG prévue les 29 et 30 juillet 2025.
L'équipe de direction de l'entreprise sera disponible pour des réunions individuelles avec les investisseurs pendant la conférence, lesquelles peuvent être organisées via les représentants de BTIG.
Belite Bio (NASDAQ: BLTE), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das Behandlungen für degenerative Netzhauterkrankungen entwickelt, gab seine Teilnahme an der bevorstehenden BTIG Virtual Biotechnology Conference bekannt, die für den 29.-30. Juli 2025 geplant ist.
Das Führungsteam des Unternehmens steht während der Konferenz für Einzelgespräche mit Investoren zur Verfügung, die über BTIG-Vertreter arrangiert werden können.
- None.
- None.
SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will be participating in the BTIG Virtual Biotechnology Conference being held July 29-30, 2025.
To schedule a one-on-one meeting with management, please reach out to your BTIG representative.
About Belite Bio
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook or visit us at www.belitebio.com.
Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com
Julie Fallon
belite@argotpartners.com
FAQ
When is Belite Bio (BLTE) presenting at the BTIG Virtual Biotechnology Conference?
How can investors schedule meetings with Belite Bio management at the BTIG conference?
What is Belite Bio's (BLTE) main business focus?
Where is Belite Bio (BLTE) headquartered?
